ImCheck Therapeutics

Merci Margot Geay pour ce bel article!

Nous avons reçu chez #ImCheck la visite de Bruno Bonnell, Secrétaire général pour l'investissement chargé de #France2030 sur le campus du CNRS à Marseille afin d'expliquer comment se créent et se développent les médicaments du futur. 🎯Un défi auquel ImCheck participe avec ferveur ! A nos côtés, étaient présents nos partenaires Emilie Royere, Eurobiomed, Aurélie PHILIPPE, CNRS, Laurent Baly, SATT Sud-Est, Emilie Garrido-Pradalie, APHM (Assistance Publique - Hopitaux de Marseille), Jean luc Chauvin, CCI Aix Marseille Provence, Jean-Baptiste Geissler, CLUB TOP 20 et l’un de nos pairs de l'immuno-oncologie, Herve Brailly, Innate Pharma ainsi que les représentants de la préfecture et des services de l’État en région : Didier MAMIS, SGAR, Jean-Luc Parrain, DRARI, Randy KOTTI, DREETS/SGAR, Adeline Fombonne, DREETS et Christophe Madrolle, représentant le président de région. Issue de l’excellence de la recherche académique française et des travaux du Pr. Daniel Olive (Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille Université), un référent mondial dans le domaine des cellules T γ9δ2 et des butyrophilines, ImCheck contribue à l’un des 10 grands objectifs sociétaux fixés par France 2030 : développer et produire en France au moins 20 nouveaux biomédicaments. Cette rencontre a été l'occasion de présenter les avancées de nos programmes d’immunothérapie dans la lutte contre les cancers et les maladies infectieuses soutenus par France2030 : #ICT01, notre candidat-médicament actuellement en essais cliniques dans différents #cancers solides et hématologiques, ainsi qu’#ICT41, un candidat prometteur dans les infections virales et bactériennes émergentes. M. Bonnell a souligné qu’ImCheck est un modèle de la dynamique de France 2030, à travers des partenariats R&D public-privé et ayant su convaincre des investisseurs français et internationaux de premier rang. Cette visite illustre le soutien de l'Etat, notamment avec financement de plus de 20 millions d’euros accordé à ImCheck il y a quelques semaines. Nous tenons à remercier tout particulièrement les agences et services de l’Etat pour leur soutien : Lise ALTER, Anne Jouvenceau-Bester et les équipes de l'Agence de l'innovation en santé, Elodie PLIQUET, Antoine D. de la Direction Générale des Entreprises, Rosalie MAURISSE, Julie Lellouche et Jérémy B. chez Bpifrance et, en région, Emilie Royere et Emmanuel Le Bouder du pôle Eurobiomed ainsi que Randy KOTTI, DREETS/SGAR et Adeline Fombonne, DREETS.

🚀 We are excited to announce that our investigational therapy ICT01, in combination with venetoclax and azacitidine, has been granted Fast Track designation by the FDA for the treatment of newly diagnosed acute myeloid leukemia (AML) patients who are ineligible for standard intensive induction chemotherapy.   This significant milestone highlights the urgent need for innovative therapies to improve outcomes for AML patients, including higher response rates and better overall survival.💉💪   Stay tuned for more data and insights at upcoming scientific meetings. Learn more 👉 https://lnkd.in/ehZJxZyy   #FDA #FastTrackDesignation #AcuteMyeloidLeukemia #ImmunoOncology #ClinicalTrials #EVICTIONtrial #ICT01

🌟 A big thank you to Biotech TV! 🌟   A huge thank you to Brad Loncar and BiotechTV for spotlighting ImCheck Therapeutics! 🎥 It was an absolute pleasure for our CEO, Pierre d'Epenoux, to discuss our groundbreaking work on butyrophilins and their role in modulating both innate and adaptive immunity by acting on circulating γδ T cells.   We are pleased to have shared the latest progress from our EVICTION clinical trials, which hold real promise in the fight against cancer. Thank you Brad for taking the time to delve into our science and help spread the word about our innovative approach and our plans for the future.   Together, we will continue to push the boundaries of immunotherapy and immuno-oncology! 💪   See you soon at #SITC 2024 Brad!   #BiotechTV #Immunotherapy #CancerResearch #ClinicalTrials #Innovation #ImCheckTherapeutics #Butyrophilins #GammaDeltaTCells

🚀 20.18 Million to accelerate the progress of two breakthrough programs in cancer and infectious diseases, in support of France's 2030 ambitious vision to deliver 20 innovative biomedicines by the end of the decade. “We are honored to be supported by the France 2030 innovation plan. It is a tribute to the progress we have achieved in the clinic and the overall potential of our novel immunotherapeutic programs. Our approach is both unique and polyvalent, enabling us to address solid tumors, hematologic malignancies and infectious diseases. This recognition from the French government and Bpifrance represents their confidence in our first-in-class therapies, which have the potential to significantly improve patients’ lives,” commented Pierre d'Epenoux d’Epenoux, Chief Executive Officer of ImCheck Therapeutics. “We look forward to providing updates from the ICT01 clinical development program as well as other corporate advances later this year.” Rosalie MAURISSE, Head of Healthcare - Innovation division at Bpifrance, added, “Under France 2030, Bpifrance supports French biotech companies that are leading drug development innovation to drive groundbreaking medical advancements. ImCheck’s pipeline programs are highly differentiated and we congratulate the company on this award and the funding to support the acceleration of two of the company’s drug candidates, fully in line with the French Government's healthcare priorities.” #France2030 #ICT01 #ICT41 #InnovationCancer #InfectiousDiseases #FT120 #FrenchTech2030 👉 https://lnkd.in/eNAQB5bi

Nous recrutons (#hiring) pour le poste de Ingénieur en biochimie des protéines en CDD (Marseille, Provence-Alpes-Côte d'Azur). Postulez dès maintenant ou partagez ce post avec votre réseau.

All of us at ImCheck Therapeutics, together with the international immuno-oncology community, are deeply saddened by the loss of Dr. Jeffrey S. Weber. His significant contributions have had a tremendous impact on cancer care. As a valued member of our Clinical Advisory Board at ImCheck for many years, he will be greatly missed.

🚀 Exciting News! ImCheck is thrilled to announce the appointment of Dr. Stephan Braun as our new Chief Medical Officer. Dr. Braun joins us to drive the clinical development of our lead candidate, ICT01, a groundbreaking γ9δ2 T cell-activating monoclonal antibody targeting BTN3A, as it advances toward later-stage clinical trials in multiple cancer indications. He will also oversee our expanding pipeline of immunotherapeutic antibodies designed to harness both innate and adaptive immune responses. With over 30 years of drug development experience from a distinguished career in the pharmaceutical industry and academic research, Dr. Braun is a tremendous addition to our team. Welcome aboard, Stephan! 🌟 #Leadership #ClinicalTrials #ICT01

🚀 Exciting News from ImCheck at #ASCO2024! 🚀 We are thrilled to share the interim data from our Phase I/II EVICTION study, which demonstrate a favorable safety profile and promising efficacy for ICT01 in combination with pembrolizumab in refractory melanoma patients. ImCheck intends to further investigate this combination regimen in refractory solid tumors, where patients have limited treatment options. Do not miss the poster session presented by Dr. Stéphane Champiat, Gustave Roussy. 📅 Saturday, June 1st, 2024 🕐 1:30–4:30 PM CST 📌 Session title: Melanoma/Skin Cancers 🔢 Abstract number: 9534 📍 Poster board: 318 #ICT01 #Pembrolizumab #ASCOAnnualMeeting #ClinicalTrials #Oncology #Melanoma See our press release : https://lnkd.in/gP-fVFpm

ImCheck Therapeutics once again recognized for its potential to become an international leader in healthcare innovation   🏆 ImCheck is a winner of the French Tech 120 program for the 5th year in a row and a winner of the new French Tech 2030 program announced nearly a year ago. 👩⚕️ ImCheck is one of the few therapeutics-focused biotech and healthcare start-up/scale-up companies selected as one of the 120 companies for the fifth edition of the French Tech Next40/120 program and as one of the 125 recipients of the first edition of the French Tech 2030 program. 💪 The awards highlight ImCheck as one of the leaders among the companies supporting the ambitions of the Innovation Santé 2030 plan.   ImCheck Therapeutics announced today that it is part of the prestigious French Tech 120 for the fifth year in a row. Being once again a #FT120 winner and one of the 125 companies selected for the #FrenchTech2030 underscores ImCheck's potential to become a world-class leader in immunotherapy. ImCheck benefits from these two programs of excellence launched by the French government, serving one of the 6 priorities of France 2030: positioning France as a sovereign European leader in healthcare innovation.   "Anchored in our regional healthcare ecosystem in Marseille and backed by a syndicate of prestigious international investors, we are delighted to once again have the support and recognition of the French government and its agencies, and intend to actively contribute to France's sovereignty in healthcare innovation. We are more determined than ever to become a champion in immunotherapy on a global scale," said Pierre d'Epenoux, CEO of ImCheck Therapeutics.   We would like to thank Clara Chappaz Lise ALTER Marina Ferrari Bruno Le Maire Gabriel Attal and Emmanuel Macron for their support. #France2030 #FT120 #FrenchTech #FrenchTech2030 #HealthInnovationAgency #Innovation #Cancer